T. Rowe Price Associates
ADMA icon

T. Rowe Price Associates’s ADMA Biologics ADMA Stock Holding History

T. Rowe Price Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.3M Sell
1,592,476
-623,809
-28% -$5.69M ﹤0.01% 1263
2026
Q1 		$20M Buy
2,216,285
+55,726
+3% +$879K ﹤0.01% 1037
2025
Q4 		$39.4M Buy
2,160,559
+4,897
+0.2% +$82.5K ﹤0.01% 879
2025
Q3 		$31.6M Buy
2,155,662
+16,422
+0.8% +$281K ﹤0.01% 936
2025
Q2 		$39M Buy
2,139,240
+28,309
+1% +$577K ﹤0.01% 794
2025
Q1 		$41.9M Buy
2,110,931
+10,293
+0.5% +$178K 0.01% 769
2024
Q4 		$36M Buy
2,100,638
+504
+0% +$9.48K ﹤0.01% 854
2024
Q3 		$42M Buy
2,100,134
+23,806
+1% +$370K ﹤0.01% 806
2024
Q2 		$23.2M Buy
2,076,328
+2,015,404
+3,308% +$16.9M ﹤0.01% 920
2024
Q1 		$403K Buy
60,924
+7,450
+14% +$40.7K ﹤0.01% 2294
2023
Q4 		$242K Buy
53,474
+5,506
+11% +$20.4K ﹤0.01% 2466
2023
Q3 		$172K Buy
47,968
+6,101
+15% +$23.5K ﹤0.01% 2549
2023
Q2 		$155K Buy
41,867
+2,118
+5% +$7.85K ﹤0.01% 2595
2023
Q1 		$132K Buy
39,749
+7,920
+25% +$27.4K ﹤0.01% 2630
2022
Q4 		$123K Buy
31,829
+2,986
+10% +$9.21K ﹤0.01% 2674
2022
Q3 		$71K Buy
28,843
+11,109
+63% +$26.7K ﹤0.01% 2787
2022
Q2 		$35K Buy
+17,734
New +$34.9K ﹤0.01% 2896

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates's ADMA Position: Q2 2026 in Review

T. Rowe Price Associates reduced its ADMA Biologics (ADMA) stake by 28% in Q2 2026, selling an estimated $5.69M and leaving 1,592,476 shares worth $13.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1263.

T. Rowe Price Associates first reported a position in ADMA in Q2 2022 and has held it in 17 quarters since. The position peaked at $42M in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • T. Rowe Price Associates held 1,592,476 shares of ADMA Biologics worth $13.3M as of Q2 2026.
  • T. Rowe Price Associates sold 623,809 ADMA Biologics shares in Q2 2026, an estimated $5.69M.
  • ADMA Biologics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1263 holding.
  • T. Rowe Price Associates first reported a position in ADMA Biologics in Q2 2022 and has held it in 17 quarters since.
  • T. Rowe Price Associates's ADMA Biologics position peaked at $42M in Q3 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.